https://www.selleckchem.com/pr....oducts/gkt137831.htm
Chemoprevention against colorectal cancer (CRC) is greatly needed. As the development of CRC involves multiple dysfunctional pathways, it is thus reasonable to combine some agents that address several pathways to achieve better chemoprotection. We aimed to explore whether the use of aspirin and selective serotonin reuptake inhibitors (SSRIs)-either as monotherapy or combined-can have a clinical benefit against CRC. We performed a nested case-control study using nationwide Swedish registers. We recruited 24,786 CRC cases and randomly m
Aimer
Commentaire
Partagez
